Alizé Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome

Results from the randomized, double blind and placebo-controlled Phase II trial show significant improvements in hyperphagia-related behavior, a key therapeutic objective in Prader-Willi Syndrome.

from Obesity / Weight Loss / Fitness News From Medical News Today http://ift.tt/1T4nzQf

Jasmine Bryant

Phasellus facilisis convallis metus, ut imperdiet augue auctor nec. Duis at velit id augue lobortis porta. Sed varius, enim accumsan aliquam tincidunt, tortor urna vulputate quam, eget finibus urna est in augue.

No comments:

Post a Comment